Creation of a novel telomere-cutting endonuclease based on the EN domain of telomere-specific non-long terminal repeat retrotransposon, TRAS1
© Yoshitake et al; licensee BioMed Central Ltd. 2010
Received: 27 May 2009
Accepted: 1 April 2010
Published: 1 April 2010
The ends of chromosomes, termed telomeres consist of repetitive DNA. The telomeric sequences shorten with cell division and, when telomeres are critically abbreviated, cells stop proliferating. However, in cancer cells, by the expression of telomerase which elongates telomeres, the cells can continue proliferating. Many approaches for telomere shortening have been pursued in the past, but to our knowledge, cutting telomeres in vivo has not so far been demonstrated. In addition, there is lack of information on the cellular effects of telomere shortening in human cells.
Here, we created novel chimeric endonucleases to cut telomeres by fusing the endonuclease domain (TRAS1EN) of the silkworm's telomere specific non-long terminal repeat retrotransposon TRAS1 to the human telomere-binding protein, TRF1. An in vitro assay demonstrated that the TRAS1EN-TRF1 chimeric endonucleases (T-EN and EN-T) cut the human (TTAGGG)n repeats specifically. The concentration of TRAS1EN-TRF1 chimeric endonucleases necessary for the cleavage of (TTAGGG)n repeats was about 40-fold lower than that of TRAS1EN alone. When TRAS1EN-TRF1 endonucleases were introduced into human U2OS cancer cells using adenovirus vectors, the enzymes localized at telomeres of nuclei, cleaved and shortened the telomeric DNA by double-strand breaks. When human U2OS and HFL-1 fibroblast cells were infected with EN-T recombinant adenovirus, their cellular proliferation was suppressed for about 2 weeks after infection. In contrast, the TRAS1EN mutant (H258A) chimeric endonuclease fused with TRF1 (ENmut-T) did not show the suppression effect. The EN-T recombinant adenovirus induced telomere shortening in U2OS cells, activated the p53-dependent pathway and caused the senescence associated cellular responses, while the ENmut-T construct did not show such effects.
A novel TRAS1EN-TRF1 chimeric endonuclease (EN-T) cuts the human telomeric repeats (TTAGGG)n specifically in vitro and in vivo. Thus, the chimeric endonuclease which is expressed from an adenoviral vector can suppress cell proliferation of cancer cells.
Telomeres are specialized structures that protect chromosomal ends from gene erosion at cell divisions, nonhomologous chromosomal end joining and nuclease attack . The DNA component of telomeres, typically 5-8 kb long, consists of tandem arrays of short, repetitive G-rich sequences--TTAGGG in vertebrates--oriented 5'- to -3' towards the end of the chromosome . Each replication of human nuclear DNA results in a 50-200 base pair loss of the telomere. After reaching a critical shortening of the telomere, the cell enters replicative senescence or undergoes programmed cell death . In striking contrast, the length of telomeres in cancer cells does not shorten during replication and remains constant over succeeding generations. This is because of the characteristic enzyme, telomerase, which is expressed in more than 80% of human cancers . Expression of telomerase is not induced in normal human tissues and somatic cells and is usually limited to germline cells. Hence, telomerase is potentially a molecular target for developing antitumour agents . However, as mentioned above, because telomeres shorten by 50-200 bases every cell division under physiological conditions, it takes a long time with conventional telomerase inhibitors (~1 month)  to induce effective telomere shortening followed by cellular senescence. In order to induce this rapidly, we investigated a novel method of shortening telomeres with the endonuclease domain of a telomere-specific non-long terminal repeat (LTR) retrotransposon, TRAS1.
Non-LTR retrotransposons, also known as long interspersed nuclear elements (LINEs), are transposable elements that insert into the genome via RNA intermediates. Most such transposable elements integrate into the genome randomly, although some LINEs have very restricted target sequences for integration . TRAS1, found in the silkworm Bombyx mori, is a typical sequence-specific LINE, which inserts between the T and A of the (TTAGG)n telomeric repeats of the silkworm . The second open reading frame (ORF2) of TRAS1 encodes an apurine/apyrimidine (AP) endonuclease-like domain (EN) at the N-terminal end . The EN domain of TRAS1 (TRAS1EN) cuts the specific target sites of (TTAGG)n/(CCTAA)n telomeric repeats during target-primed reverse transcription, which is an essential process for LINEs . TRAS1EN also cleaves the vertebrate telomeric repeats, (TTAGGG)n and several other telomere sequences in different species . Thus, if TRAS1EN could cut telomeres in human cancer cells specifically and effectively, we hypothesized that the proliferation of cancer cells would be inhibited.
We have determined the crystal structure of TRAS1EN , which is basically similar to the AP endonuclease family, but has a special beta-hairpin at the DNA binding surface. Mutational studies of TRAS1EN indicated that the Asp-130 and β10-β11 hairpin structures are involved in specific recognition of telomeric repeats. We also analysed the structure of the EN of the silkworm 28S rDNA-specific LINE R1 (R1BmEN) and found that a Y98A mutant of R1BmEN on the DNA binding surface had altered cleavage patterns [12, 13]. These results suggest an important role of the DNA binding surface in the EN of LINE for target sequence recognition and for the de novo design of a novel sequence-specific EN with altered sequence specificity for human telomeric repeats. Although in silico screening has been done for the homing endonuclease I-Mso I  to redesign its DNA binding and cleavage, it is still difficult to redesign in silico for changing the specificity of EN of LINE .
TRAS1EN cleaves human (TTAGGG)n telomeric repeats but its activity level and specificity seemed to be insufficient for practical application. In order to increase its ability, we used the human telomere-binding protein TRF1. The shelterin complex, consisting of six telomere-specific proteins including TRF1, protects the chromosomal ends. TRF1 has a Myb domain at its C-terminal end, which recognizes the double-strand DNA sequence TTAGGGTTA  and controls telomere length negatively . We created chimeric endonucleases of TRAS1EN with either a full length of TRF1 or only the Myb domain of TRF1 and examined their abilities to cut vertebrate telomeric repeats. Here, we show that these TRAS1EN-TRF1 chimeric endonucleases cut TTAGGG repeats specifically in vitro and in vivo. They induce telomeric shortening and suppress cell proliferation when introduced into cancer cells.
Construction and expression of chimeric endonucleases
Chimeric endonucleases cleave human telomeric repeats effectively
Activity and specificity of the chimeric endonucleases
Binding and cleavage of telomeric repeats by chimeric endonucleases
In order to understand how our chimeric endonucleases cut the telomeric repeats, we analysed cleavage sites in end-labelled oligo DNA TR5 containing (TTAGGG)5 repeats, digested with chimeric endonucleases (Additional file 4). We found that chimeric TRAS1EN endonucleases cleaved the T-A junction of the TTAGGG strand and the C-T junction of the CCCTAA strand, which is consistent with the cleavage sites for TRAS1EN . This demonstrates that the specificity of these chimeric endonucleases was not changed even though TRAS1EN was fused with TRF1 domains. Interestingly, the cleavage sites of the two chimeric FN endonucleases (cleavage site (C|CCTAA) in T-FN and (CCCTA|A) in FN-T) on the CCCTAA strand were different from each other. The linker lengths of T-FN and FN-T are quite different, which might affect their respective cleavage sites on the CCCTAA strand .
Next, we performed electrophoretic mobility shift assays (EMSAs) to test the binding capacities of chimeric endonucleases to the telomeric repeats. Like TRF1 (T) and its Myb domain (M) , all EN and FN chimeric endonucleases bound to the telomeric oligonucleotide TR5 (Additional file 5a), but not to the nontelomeric sequence (NTR) (Additional file 5b), suggesting that chimeric endonucleases recognize telomeric repeats based on the binding specificity of TRF1.
TRAS1EN fused with TRF1 cuts telomeric repeats in human cells effectively
Subcellular localization of telomere specific chimeric endonucleases
Indirect immunofluorescence of γH2AX, which is a double-strand-break marker , visualized telomere cleavage by chimeric endonucleases in U2OS cells (Figure 5b). Only after infection with the T-EN or EN-T adenovirus did we observe many co-localized spots of chimeric endonuclease and γH2AX (yellow signals in the merged and enlarged images). There were some background γH2AX signals in PML bodies [22, 23] without virus infection. Using NIH Image J software, we quantified colocalization of HA and γH2AX signals (Figure 5c) and found that 34% of T-EN and 27% of EN-T foci localized at double-strand breaks. These observations confirmed that both T-EN and EN-T localize at telomeres and cut telomeric DNA.
Inhibition of cell proliferation
We examined whether the telomere shortening induced by chimeric EN endonucleases could repress the cell proliferation directly. A low concentration of recombinant adenoviruses was added to U2OS and HFL-1 human cells at each passage, every 3-4 days. Twenty-five days after viral infection, the growth of U2OS tumour cells infected with EN-T-expressing adenovirus was inhibited at the higher dose (Figure 6b). In contrast, U2OS cells infected with adenoviruses expressing chimeric proteins, G-T, FN-T, ENmut-T and EN showed normal growth similar to the cells expressing only GFP (G). We further analysed HFL-1 fibroblasts, which have no telomerase activity to elongate shortened telomere. The growth of HFL-1 cells infected with EN-T virus was more clearly inhibited than that of U2OS with the same virus (Figure 6c, d). HFL-1 cell cultures infected with EN-T adenovirus titres of 8.8 pfu/ml were dead by day 17 after infection.
Type IIS restriction endonucleases (REases) such as Fok I and Bmr I, which have a specific DNA binding domain and a nonspecific DNA cleavage domain separately, are useful to create new sequence-specific endonucleases [18, 27]. For this purpose, DNA binding domains such as the Z-conformation-specific Za domain of human RNA adenosine deaminase, Gal4 and zinc finger motifs are fused with the Fok I DNA cleavage domain (FN). The most extensively studied group of chimeric nucleases is based on zinc finger nucleases (ZFNs), because zinc finger motifs can be designed to bind a large range of DNA sites . It was reported that ZFNs could cleave their chromosomal targets in frog oocytes, Drosophila, plant cells, Caenorhabditis elegans and human cells [29, 30]. However, so far, there has been no report of telomere specific endonuclease being created. The cleavage domain of type IIS REase has no specificity for any target sequence, but the endonuclease domains found in several target-specific LINEs are highly sequence-specific. Thus, the coupling of such a LINE endonuclease with a DNA-binding protein will produce an endonuclease with improved site-specificity.
To cut human (TTAGGG)n telomeric repeats specifically, we first tried to use TRAS1EN (EN), the endonuclease domain from the silkworm telomere-specific LINE TRAS1, but it had insufficient activity and specificity. Therefore, we tried to make chimeric endonucleases of EN or FN fused with the human telomeric repeat binding protein TRF1. Five chimeric EN endonucleases and two chimeric FN endonucleases cut the telomeric repeats (pTR80) specifically but did not cut the nontelomeric sequence in the same enzyme concentration (pNTR; Figures 2, 3). There was no major difference in specificity for pTR80 with various constructs (Figure 3) which suggested that the domain constituents and structures of chimeric endonucleases do not affect their activities, and that the TRF1 Myb domain included in all chimeric enzymes is essential for cleavage specificity to human telomeric repeats. FN-T and T-FN digested both strands of (TTAGGG/CCCTAA)n repeats with different cleavage sites on the top strand, but chimeric enzymes based on TRAS1EN digested both strands specifically as does TRAS1EN itself (Additional file 4), so the specificity of TRAS1EN is left unaffected even in the context of chimeric constructs. The EC50 for cutting telomeric repeat DNA of FN-T, the most active enzyme in vitro, was 0.011 μM and the value of EN-T was 0.10 μM (Figure 3j). Both values seem low enough to be functional in the cell, in comparison with other active enzymes such as ZFN  (EC50, ~0.01 μM) and artificial homing endonuclease  (EC50, ~0.2 μM).
When these chimeric endonucleases were expressed in cancer cells, T-EN and EN-T moved to telomeres (Figure 5a) where they induced double-strand breaks (Figure 5b, c) and telomere digestion (Figure 4e). In contrast, T-FN could not move into the nucleus (Figure 5a) and T-FN and FN-T showed insufficient double-strand breaks at telomere (Figure 5c). Thus, neither produced telomere digestion in vivo (Figure 4a, c), although they have strong activities in vitro. T-FN may lose its NLS function within the TRF1 region because of conformational changes. In addition, there are several reports of chromosomal double strand breaks in vivo by FN chimeric endonuclease [29, 30] but the prokaryotic enzyme FN might have less endonuclease activity for telomeres with a eukaryotic chromatin structure than the telomere-specific endonuclease TRAS1EN.
Through telomere shortening, the cells expressing EN-T, showed higher levels of cellular senescence markers (Figure 7c-e) and suppressed cell proliferation (Figure 7a). Thus, this chimeric endonuclease has the potential to be used as anticancer reagents. During the progression of cancer, one of the important mechanisms is telomerase activation which circumvents the telomere-dependent pathways of replicative senescence and crisis . The lack of telomerase expression in most normal somatic cells makes this enzyme an attractive target when designing anticancer therapeutics. Thus, the inhibition of telomerase by a dominant negative hTERT mutant in human acute leukemia cells caused not only telomere shortening but also induction of apoptosis . However, it took more than 40 days and such an approach would be valid only in the telomerase positive cells. Here, we have succeeded in developing a novel approach to shorten telomeres directly and quickly by TRAS1EN chimeric endonucleases. Compared with telomerase inhibitors, which are not effective in telomerase-negative cancer cells , these TRAS1EN chimeric enzymes have the great advantage of being effective not only in the telomerase-positive cancer cells but also in telomerase-negative cancer cells such as U2OS. Future modifications of the expression vectors using cancer-specific enhancer-promoters, such as the hTERT promoter and the hypoxia-inducible enhancer , to restrict the expression of the chimeric endonuclease in specific cancer cells could reduce unwanted effects on normal cells. This paper shows the concept of using such chimeric endonuclease to inhibit the growth of cancer cells by telomeric repeat shortening.
We created novel chimeric endonucleases to cut human telomeres by fusing the endonuclease domain of the silkworm's telomere specific non-LTR retrotransposon TRAS1 to the human telomere-binding protein, TRF1. These chimeric endonucleases were able to cut telomeric repeats specifically and effectively not only in vitro but also in human cell lines in vivo, and EN-T-expressing adenovirus suppressed the cell growth of cancer cells in a few weeks. This report shows the possibility of cancer gene therapy by rapid telomere shortening.
Cloning of TRF1, TRAS1EN and FN in the expression vector
Three-dimensional modelling of chimeric proteins was performed with PyMol v0.99-rc6 http://www.pymol.org. We started from the co-crystal structure of the Myb domain of TRF1 and DNA (PDB ID: 1W0T), then overlaid EN (PDB ID: 1WDU) or FN (PDB ID: 1FOK). Although the co-crystal structure of EN and DNA has not yet been clarified, the interaction between EN and DNA was surmized via homology modelling using the crystal structure of DNaseI (PDB ID: 1DNK) . The TRF1, TRF1 Myb domain, and TRF1 NLS-Myb domain were amplified by polymerase chain reaction (PCR) with Pfu Turbo DNA polymerase (Stratagene, CA, USA) using primers TRF1-f-Nco-Nhe, TRF1M-f-Nco-Nhe, TRF1NM-f-Nco-Nhe and TRF1-b-Sal-Not (Additional file 6) from HEK293 cell cDNA. EN and EN(H258A) were amplified using primers T1EN-f-Sal-Nhe and T1EN-b-Nco-Not (Additional file 6) from plasmid pHisT1EN or pHisT1EN(H258A)  and FN was amplified using primers FN-f-Sal-Nhe and FN-b-Nco-Not (Additional file 6) from plasmid pML109RM119-1 (ATCC biological resource centre). All primers were designed to contain restriction endonuclease sites and PCR products were digested with the corresponding enzymes (Figure 1). The products were cloned into the pET21b expression vector (Novagen), which is an expression vector for E. coli and contains a His tag in the C-terminal end. To produce chimeric constructs, in the case of pET21b-EN-T vector, TRF1 was subcloned into pET21b digested with Nhe I and Not I, and then TRAS1EN was subcloned into pET21b-TRF1 digested with Nhe I and Nco I. Other vectors were constructed similarly. The insert sequence of a candidate clone was confirmed. Adenovirus expression vectors were constructed from pAxCAwtit (TAKARA), which contains the CAG (chicken beta-actin promoter and cytomegalovirus immediate-early enhancer) promoter. Insert sequences were amplified from each pET21b vector using 5'-phosphorylated primers Kozak-HA-rbs and His tag (Additional file 6) and were ligated into pAxCAwtit digested with Swa I. Recombinant adenoviruses were generated according to the manufacturer's procedures. Recombinant pAxCAwtit vectors were digested with Nsp V and the linearized adenovirus DNAs were transfected into human 293 cells. Recombinant adenoviruses were generated in 293 cells. The map of adenovirus vector is shown in Additional file 7.
Expression and purification of chimeric endonucleases
The plasmids containing chimeric endonucleases were transformed into the E. coli strain Rosetta2(DE3)/pLysS (Novagen) plus pG-KJE8 (TAKARA). We used the Rosetta2 E. coli strain because this strain carried a plasmid containing tRNA genes to decode rare E. coli codons, and the strain was designed to enhance the expression of eukaryotic proteins. The plasmid pG-KJE8, which contains chaperons to facilitate protein folding and enhance production of active proteins, was co-transformed. Transformants were grown in 10 ml LB containing 50 μg/ml ampicillin, 20 μg/ml chloramphenicol, 100 μg/ml kanamycin, 5 ng/ml tetracycline, and 0.5 mg/ml L-arabinose culture at 37°C until the optical density at 600 nm (OD600) reached 0.6. Isopropyl-β-D-thiogalactopyranoside (IPTG) was then added to a final concentration of 1 mM, and incubation was continued for 12 h at 25°C. Protein purification was carried out according to the manufacturer's protocol for Ni-NTA agarose (Qiagen, CA, USA). Glycerol up to a concentration of 5% was added to the eluted proteins which were stored at -80°C. Eluates were run on SDS-PAGE and the target proteins were detected as bands of predicted molecular masses. We calculated the percentage of the target protein in the total eluted proteins from Additional file 2b by quantification with ImageJ v. 1.34s (National Institutes of Health [NIH], MD, USA). The concentrations of the total eluted proteins were determined by Bradford assay using Proteostain Kit (Dojindo, MD, USA).
Assays for endonucleolytic activities
The telomeric repeat plasmid pTR80 was constructed from a PCR product of an extended primer dimer of (TTAGGG)5 and (CCCTAA)5 primers. A non-telomeric repeats (NTR) sequence was randomly selected from human mRNA, and 2022-2672 bp of Tat-SF1 (GenBank accession number U76992) was amplified with primers dT18 and NTR-f (Additional file 6) and cloned into the pGEM T-Easy vector (Promega, WI, USA). For quantitative chimeric endonuclease activity assays, plasmid pTR80 and pNTR were digested with the restriction endonuclease Sca I to make a linear substrate with telomeric repeats positioned in the centre of the DNA strand. Then, DNA was purified using the PCR clean-up kit (Sigma, NY, USA). DNA concentration was determined spectrophotometrically at 260 nm. Chimeric endonuclease was added to 10 μl of reaction buffer containing 1.6 ng/μl substrate DNA. Samples were incubated for 1 h at 25°C, and the reaction products were analysed by agarose gel electrophoresis. Ethidium bromide-stained gels were digitized with PrintGraph (Atto, Tokyo, Japan). The intensity of the product bands was quantitated using ImageJ v. 1.34s (NIH). Assays for oligonucleotide endonucleolytic activities were performed as described previously . Oligonucleotides were labelled at the 5' end by the enzymatically catalyzed transfer of 32P from [γ-32P] adenosine triphosphate (ATP) with T4 polynucleotide kinase. The oligonucleotide concentration was fixed at 100 nM with adding nonlabelled oligonucleotides. The reaction buffer for chimeric endonucleases contained 5 mM HEPES-KOH (pH 7.9), 10 mM NaCl, 2 mM MgCl2, 100 μg/ml BSA and 500 nM non-specific oligonucleotide, NTR to suppress non-specific binding of misfolded chimeric endonuclease to non-telomeric sequence. This mixture was treated with a purified chimeric endonuclease in 10 μl of reaction buffer for 1 h at 25°C. The reaction mixture was denatured in a loading buffer containing 75% formamide for 5 min at 95°C, immediately chilled on ice and run on a 28% Long Ranger polyacrylamide denaturing sequencing gel (Lonza, Basel, Switzerland). Quantitation of the reaction products was carried out with a BAS 5000 imaging analyser system (Fujifilm).
Various-sized telomeric repeat oligonucleotides were end-labelled with T4 polynucleotide kinase and [γ-32P] ATP and were used as molecular size markers: dG8, dG14, dG20, dG26, dC9, dC15, dC21 and dC27 (Additional file 6).
Electrophoretic mobility-shift assay
DNA probes were 5'-end-labelled as described earlier , and were gel-purified. About 15 fmol of DNA was labelled in a 10 μl reaction and the final probe concentration in binding assays was <10 nM. Binding reactions were carried out by incubating the indicated amounts of protein (see figure legends for details) in 10 μl of a reaction mix of 20 mM Hepes (pH 7.9), 150 mM KCl, 0.1 mM EDTA, 1 mM DTT, 4% Ficoll, 5% glycerol, 0.1 mg/ml of BSA and 3 ng/μl salmon sperm DNA. Samples were incubated at 4°C for 60 min and then run on native 5% polyacrylamide gels as described .
Cell cultures and adenovirus production
Two hundred and ninety-three U2OS, CCF-STTG1 and HFL-1 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum . All cell lines were provided from the RIKEN BioResource Center (Ibaraki, Japan). Cells were routinely passaged at 80% confluence. Adenoviruses were used as freeze-thaw lysates, and their titres were estimated following the manufacturer's procedure of the Adenovirus Expression Vector Kit (TAKARA, WI, USA) for each virus (n = 16). Transfections were performed with FuGene HD (Roche) according to the manufacturer's procedure. Four separate microscope images were used for counting the number of cells with CellProfiler .
Telomere length measurement
Genomic DNA was purified with PUREGENE (Gentra, WA, USA) and digested with HinfI. Digests were separated on a native 0.8% agarose gel, blotted in 0.4 M NaOH onto a Hybond N+ membrane (Amersham, Uppsala, Sweden) and hybridized with the RI-labelled (CCCTAA)5 and 1490-1467 bp of L1 (Additional file 6; GenBank accession number X52235.1) probes in hybridization buffer (6× saline-sodium citrate [SSC], 1% sodium dodecyl sulphate [SDS], 5× Denhardt's solution, 2.5 μg/ml salmon sperm DNA) at 37°C for 12 h. The membrane was washed several times with wash buffer (4× SSC, 0.1% SDS) for 10 min at 37°C. Quantitation of the reaction products was carried out with a BAS 5000 imaging analyser system (Fujifilm).
Cells were trypsinized, washed once with PBS and subsequently lysed in 200 mM Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 200 μM DTT and 0.2% bromophenol blue. Lysates were separated on SDS polyacrylamide gels (29:1 acrylamide: bisacrylamide, 8% gel) and transferred onto BioTrace PVDF (Pall) for 70 min at 14 V. Membranes were preincubated in TBST (0.1% Tween20 in 1× TBS) containing 5% BSA for 30 min and then incubated with primary antibodies in Can Get Signal Solution 1 (TOYOBO, Osaka, Japan) for 1 h, followed by three 10 min washes with TBST. The following antibodies were used: TRF2, IMGENEX #IMG-124A; γ-H2AX, LPBIO #AR-0149; HA, BETHYL #A190-108A; p53, EXBIO #11-114-C100; p16INK4a, Thermo #MS-383-P0; α-Tubulin, CEDARLANE #CLT9002 and β-Actin, Abcam #ab8226. Membranes were incubated for 1 h with horseradish peroxidase conjugated anti-mouse or anti-rabbit antibodies (Amersham) in Can Get Signal Solution 2 (TOYOBO) and were developed using the ECL PLUS system (Amersham). All samples were loaded in the same gel and the blotted membrane was re-stained with different antibody after stripping in 2% SDS, 100 mM β-mercaptoethanol and 62.5 mM Tris-HCl pH 7 at 50°C for 30 min.
The cellular localization of chimeric endonucleases was visualized through indirect immunofluorescence. Cells were grown on glass-bottomed dishes, washed once with PBS, fixed with methanol, and permeabilized in a Triton X-100 solution (0.5% Triton X-100 in phosphate-buffered saline) four times for 10 min. The cells were subsequently blocked for 1 h at 25°C in 10% sheep serum, stained with primary or fluorescence-conjugated secondary antibodies for 1 h at 37°C, and then visualized under an Olympus IX51 fluorescence microscope. Anti-TRF2 antibody (IMGENEX, CA, USA; #IMG-124A) was used to detect telomere, because TRF2 is another telomere binding protein being independent of TRF1, and anti-HA antibody (BETHYL, TX, USA; #A190-108A) was used to detect chimeric endonucleases. Secondary antibodies were Alexa Fluor 488 or 555-conjugated goat anti-mouse or anti-rabbit antibodies (Molecular Probes, CA, USA).
Senescence-associated beta-galactosidase staining
Senescence-associated beta-galactosidase (SA β-gal) activity at pH 6.0 is a commonly used cellular senescence marker . Positive cells were detected by the modified method of Dimri et al. . The monolayers of cells were washed with PBS and then fixed with 1% glutaraldehyde for 5 min. The cells were washed again twice with PBS, then staining solution was added [1 mg/ml 5-bromo-4-chloro-3-inolyl-b-D-galactoside (X-gal), 40 mM sodium phosphate, pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, 2 mM MgCl2]. After the cells were further incubated at 37°C for 24 h, the percentage of stained cells was counted. The number of blue structures was counted in four fields (from a total of average 3.76 × 103 cells).
Fok I cleavage domain
long interspersed nuclear element
long terminal repeat
nuclear localization signal
phosphate buffered saline
polymerase chain reaction
sodium dodecyl sulfate
zinc finger nuclease.
We thank Drs M Kondo, M O Futahashi, N Maita and A Kuroki for their helpful suggestions and critical reading of the original manuscript. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan and the Program for Promotion of Basic Research Activities for Innovative Bioscience (PROBRAIN) [HF].
- Blackburn E: Telomere states and cell fates. Nature. 2000, 408 (6808): 53-56. 10.1038/35040500.View ArticlePubMedGoogle Scholar
- Blackburn EH: Structure and function of telomeres. Nature. 1991, 350 (6319): 569-573. 10.1038/350569a0.View ArticlePubMedGoogle Scholar
- Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature. 1990, 345 (6274): 458-460. 10.1038/345458a0.View ArticlePubMedGoogle Scholar
- Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 1994, 266 (5193): 2011-2015. 10.1126/science.7605428.View ArticlePubMedGoogle Scholar
- Shin-Ya K: Novel antitumor and neuroprotective substances discovered by characteristic screenings based on specific molecular targets. Biosci Biotechnol Biochem. 2005, 69 (5): 867-872. 10.1271/bbb.69.867.View ArticlePubMedGoogle Scholar
- Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S, Moore MA: Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood. 2004, 103 (1): 258-266. 10.1182/blood-2003-02-0546.View ArticlePubMedGoogle Scholar
- Kojima K, Fujiwara H: Evolution of target specificity in R1 clade non-LTR retrotransposons. Mol Biol Evol. 2003, 20 (3): 351-361. 10.1093/molbev/msg031.View ArticlePubMedGoogle Scholar
- Okazaki S, Ishikawa H, Fujiwara H: Structural analysis of TRAS1, a novel family of telomeric repeat-associated retrotransposons in the silkworm, Bombyx mori. Mol Cell Biol. 1995, 15 (8): 4545-4552.PubMed CentralView ArticlePubMedGoogle Scholar
- Anzai T, Takahashi H, Fujiwara H: Sequence-specific recognition and cleavage of telomeric repeat (TTAGG)(n) by endonuclease of non-long terminal repeat retrotransposon TRAS1. Mol Cell Biol. 2001, 21 (1): 100-108. 10.1128/MCB.21.1.100-108.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Takahashi H, Fujiwara H: Transplantation of target site specificity by swapping the endonuclease domains of two LINEs. EMBO J. 2002, 21 (3): 408-417. 10.1093/emboj/21.3.408.PubMed CentralView ArticlePubMedGoogle Scholar
- Maita N, Anzai T, Aoyagi H, Mizuno H, Fujiwara H: Crystal structure of the endonuclease domain encoded by the telomere-specific long interspersed nuclear element, TRAS1. J Biol Chem. 2004, 279 (39): 41067-41076. 10.1074/jbc.M406556200.View ArticlePubMedGoogle Scholar
- Maita N, Aoyagi H, Osanai M, Shirakawa M, Fujiwara H: Characterization of the sequence specificity of the R1Bm endonuclease domain by structural and biochemical studies. Nucleic Acids Res. 2007, 35 (12): 3918-3927. 10.1093/nar/gkm397.PubMed CentralView ArticlePubMedGoogle Scholar
- Feng Q, Schumann G, Boeke J: Retrotransposon R1Bm endonuclease cleaves the target sequence. Proc Natl Acad Sci USA. 1998, 95 (5): 2083-2088. 10.1073/pnas.95.5.2083.PubMed CentralView ArticlePubMedGoogle Scholar
- Ashworth J, Havranek JJ, Duarte CM, Sussman D, Monnat RJ, Stoddard BL, Baker D: Computational redesign of endonuclease DNA binding and cleavage specificity. Nature. 2006, 441 (7093): 656-659. 10.1038/nature04818.PubMed CentralView ArticlePubMedGoogle Scholar
- Repanas K, Zingler N, Layer L, Schumann G, Perrakis A, Weichenrieder O: Determinants for DNA target structure selectivity of the human LINE-1 retrotransposon endonuclease. Nucleic Acids Res. 2007, 35 (14): 4914-4926. 10.1093/nar/gkm516.PubMed CentralView ArticlePubMedGoogle Scholar
- Broccoli D, Smogorzewska A, Chong L, de Lange T: Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet. 1997, 17 (2): 231-235. 10.1038/ng1097-231.View ArticlePubMedGoogle Scholar
- van Steensel B, de Lange T: Control of telomere length by the human telomeric protein TRF1. Nature. 1997, 385 (6618): 740-743. 10.1038/385740a0.View ArticlePubMedGoogle Scholar
- Kim YG, Cha J, Chandrasegaran S: Hybrid restriction enzymes: zinc finger fusions to FokI cleavage domain. Proc Natl Acad Sci USA. 1996, 93 (3): 1156-1160. 10.1073/pnas.93.3.1156.PubMed CentralView ArticlePubMedGoogle Scholar
- Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T: Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng. 2001, 14 (8): 529-532. 10.1093/protein/14.8.529.View ArticlePubMedGoogle Scholar
- Li L, Chandrasegaran S: Alteration of the cleavage distance of FokI restriction endonuclease by insertion mutagenesis. Proc Natl Acad Sci USA. 1993, 90 (7): 2764-2768. 10.1073/pnas.90.7.2764.PubMed CentralView ArticlePubMedGoogle Scholar
- Broccoli D, Chong L, Oelmann S, Fernald A, Marziliano N, van Steensel B, Kipling D, Le Beau M, de Lange T: Comparison of the human and mouse genes encoding the telomeric protein, TRF1: chromosomal localization, expression and conserved protein domains. Hum Mol Genet. 1997, 6 (1): 69-76. 10.1093/hmg/6.1.69.View ArticlePubMedGoogle Scholar
- Takai H, Smogorzewska A, de Lange T: DNA damage foci at dysfunctional telomeres. Curr Biol. 2003, 13 (17): 1549-1556. 10.1016/S0960-9822(03)00542-6.View ArticlePubMedGoogle Scholar
- Mirzoeva O, Petrini J: DNA damage-dependent nuclear dynamics of the Mre11 complex. Mol Cell Biol. 2001, 21 (1): 281-288. 10.1128/MCB.21.1.281-288.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Jacobs J, de Lange T: p16INK4a as a second effector of the telomere damage pathway. Cell Cycle. 2005, 4 (10): 1364-1368.View ArticlePubMedGoogle Scholar
- Deng Y, Chan S, Chang S: Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008, 8 (6): 450-458. 10.1038/nrc2393.PubMed CentralView ArticlePubMedGoogle Scholar
- Ohki R, Ishikawa F: Telomere-bound TRF1 and TRF2 stall the replication fork at telomeric repeats. Nucleic Acids Res. 2004, 32 (5): 1627-1637. 10.1093/nar/gkh309.PubMed CentralView ArticlePubMedGoogle Scholar
- Chan S, Bao Y, Ciszak E, Laget S, Xu S: Catalytic domain of restriction endonuclease BmrI as a cleavage module for engineering endonucleases with novel substrate specificities. Nucleic Acids Res. 2007, 35 (18): 6238-6248. 10.1093/nar/gkm665.PubMed CentralView ArticlePubMedGoogle Scholar
- Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, Eichtinger M, Jiang T, Foley JE, Winfrey RJ, Townsend JA, Unger-Wallace E, Sander JD, Müller-Lerch F, Fu F, Pearlberg J, Göbel C, Dassie JP, Pruett-Miller SM, Porteus MH, Sgroi DC, Iafrate AJ, Dobbs D, McCray PB, Cathomen T, Voytas DF, Joung JK: Rapid 'open-source' engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell. 2008, 31 (2): 294-301. 10.1016/j.molcel.2008.06.016.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu J, Kandavelou K, Chandrasegaran S: Custom-designed zinc finger nucleases: what is next?. Cell Mol Life Sci. 2007, 64 (22): 2933-2944. 10.1007/s00018-007-7206-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Carroll D: Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther. 2008, 15 (22): 1463-1468. 10.1038/gt.2008.145.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakajima A, Tauchi T, Sashida G, Sumi M, Abe K, Yamamoto K, Ohyashiki J, Ohyashiki K: Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia. 2003, 17 (3): 560-567. 10.1038/sj.leu.2402825.View ArticlePubMedGoogle Scholar
- Guo Z, Li Q, Bartlett D, Yang J, Fang B: Gene transfer: the challenge of regulated gene expression. Trends Mol Med. 2008, 14 (9): 410-418. 10.1016/j.molmed.2008.07.003.View ArticlePubMedGoogle Scholar
- Yu EY, Kim SE, Kim JH, Ko JH, Cho MH, Chung IK: Sequence-specific DNA recognition by the Myb-like domain of plant telomeric protein RTBP1. J Biol Chem. 2000, 275 (31): 24208-24214. 10.1074/jbc.M003250200.View ArticlePubMedGoogle Scholar
- Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps M: Construction of adenovirus vectors through Cre-lox recombination. J Virol. 1997, 71 (3): 1842-1849.PubMed CentralPubMedGoogle Scholar
- Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM: CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006, 7 (10): R100-10.1186/gb-2006-7-10-r100.PubMed CentralView ArticlePubMedGoogle Scholar
- Dimri G, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano E, Linskens M, Rubelj I, Pereira-Smith O: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995, 92 (20): 9363-9367. 10.1073/pnas.92.20.9363.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.